Fiche publication
Date publication
février 1998
Journal
QJM : monthly journal of the Association of Physicians
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GUILLEMIN Francis
Tous les auteurs :
Wahl DG, De Maistre E, Guillemin F, Regnault V, Perret-Guillaume C, Lecompte T
Lien Pubmed
Résumé
We studied the prognostic significance of antiphospholipid antibodies for recurrence of venous thromboembolism (VTE), in 71 patients admitted for acute VTE (deep-vein thrombosis or pulmonary embolism) in a single internal medicine unit. Lupus anticoagulant (LA), antibodies directed against beta 2-glycoprotein I (beta 2GPI) and antibodies against both beta 2GPI and a mixture of phospholipids (cardiolipin, phosphatidylserine and phosphatidic acid) (APAs) were measured. The patients were followed-up (mean 4.9 years) to determine the time to the next VTE. We found LA in nine patients, anti-beta 2GPI antibodies in seven patients and APAs in six patients. The cumulative risk of recurring VTE was higher in patients with beta 2GPI-binding antibodies (hazard ratio 12.6, 95% CI 1.5-104.9; p = 0.0029). The risk associated with APAs was 11.5 (95% CI 1.3-98.9; p = 0.0049) and that for LA was 3.7 (95% CI 0.9-15.6; p = 0.055). The risk of VTE recurring was higher both in patients with antibodies directed against beta 2GPI, and in patients with antibodies directed against beta 2GPI and a mixture of phospholipids, than in patients without these antibodies.
Mots clés
Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, blood, Antibodies, Antiphospholipid, blood, Biomarkers, blood, Cohort Studies, Female, Glycoproteins, immunology, Humans, Lupus Erythematosus, Systemic, complications, Male, Middle Aged, Phospholipids, immunology, Recurrence, Regression Analysis, Risk Factors, Thromboembolism, etiology, beta 2-Glycoprotein I
Référence
QJM. 1998 Feb;91(2):125-30
